Regulation & Compliance

In an age of AI traders and instant data, one expert argues that the most valuable asset remains timeless: human discipline. But is this enough to navigate our volatile future?

Great Estate Blockchain divests its main revenue source after a flawed deal structure implodes, leaving the penny-stock firm seeking a new identity.

BlackRock Canada is shifting five iShares ETFs to new indices, updating the core methodology to include intangibles and buybacks, a move expected to create capital gains.

NeoGenomics is raising $275M via convertible notes. We dissect the sophisticated financing, from dilution-hedging calls to the market impact for investors.

Exodus Movement's May metrics reveal a complex picture: rising transaction volumes and strategic asset shifts signal deep engagement, but a flat user count raises questions.

The financial giant sets its 2027 Investor Day. Beyond the date, it's a signal of intent for navigating a fractured world with a $4.9T balance sheet.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

Icelandic biotech Alvotech seeks $125M in a complex dual offering to advance its low-cost drug pipeline, but regulatory hurdles and financial pressures loom.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

CrowdStrike's new Continuous Identity platform isn't just a product; it's a foundational shift for securing the coming wave of autonomous AI agents.

A new report reveals less than half of Ontario's long-term care homes got proactive inspections, exposing a deep disconnect between policy and resident safety.

A Texas-based, private equity-backed firm just acquired a beloved local dermatology practice. It’s a story of national expansion, but what does it mean for care?

A small town lost a legal fight with a mega-church over a temple's height. Now, its public appeal is testing the limits of a powerful federal law.

Immuta's expanded Databricks partnership introduces a new security paradigm for autonomous AI, promising to turn a critical risk into a commercial advantage.

The electric boat innovator executes another reverse stock split to stay on Nasdaq, but a history of similar moves raises questions about its financial health.

xSuite's deep SAP integration and advanced AI earned it a 'Strong Performer' rank in Forrester's 2026 AP automation report, praised for high accuracy.

Northann Corp. is back in the NYSE's good graces, but a closer look reveals a risky path. Can its innovative 3D printing tech overcome financial headwinds?

BVI's new European training hub isn't just a facility; it's a response to a critical skills gap in medicine, revealing how industry is shaping our trust in healthcare.

A landmark study proves drones can safely transport human kidneys, a breakthrough that could slash wait times and save lives. But can we clear the regulatory hurdles?

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.